The inventive step was to create a vector out of it," Themis CEO and co-founder Erich Tauber told BioWorld International

Jacques Lemmens, CEO of Synthon, told BioWorld International that ADCs "represent the future of antibody treatments for cancer

We're hoping to get that trial completed within 18 months," ReNeuron CEO Michael Hunt told BioWorld International

plc. (See BioWorld International, Aug. 3, 2011.) Lynch, a former chairman and CEO of Amarin, is still in situ, but several other board members parted company with ChronTech last month, including William Hall, a virologist based at University College Dublin

plc. (See BioWorld International, Aug. 3, 2011.) Lynch, a former chairman and CEO of Amarin, is still in situ, but several other board members parted company with ChronTech last month, including William Hall, a virologist based at University College Dublin

Olav Hellebo, CEO of Oslo, Norway-based Clavis, told BioWorld International it was the end for the technology...The fall was a smaller hit in relative terms than the news of the Phase II failure of CO-101 on Nov. 12, 2012, when Clavis' share price dropped from NOK66 to NOK8. (See BioWorld International, Nov. 14, 2012.)

For stock-based deals that have been completed, the final value was calculated based on the closing price before the merger's completion was announced. ** Denotes the date the item ran in BioWorld International. @ Conversions of non-U.S

Late last year, the Cell Therapy Catapult Center, a UK-based incubator for the cell therapy sector, determined that there is limited investment in the field from commercial backers, with big pharma observing and waiting, while SMEs (small and medium-sized enterprises) that are active lack the finance and breadth of resources needed to advance rapidly. (See BioWorld International, Dec. 12, 2012.) The center cited a lack of understanding within the pharma industry of what types of therapies are

It's a nice benchmark, if you will, for a first-in-class drug for dry eye," Garheng Kong, general partner at Menlo Park, Calif.-based Sofinnova and SARcode board member, told BioWorld International...Jessica Mann, spokeswoman for Dublin, Ireland-based Shire, told BioWorld International the company was attracted to the asset because of its product differentiation potential and because it targets an area with significant unmet need

has been used in other drugs, but never combined with ibuprofen before," Stoloff told BioWorld International

It's a nice benchmark, if you will, for a first-in-class drug for dry eye," Garheng Kong, general partner at Menlo Park, Calif.-based Sofinnova and SARcode board member, told BioWorld International...Jessica Mann, spokeswoman for Dublin, Ireland-based Shire, told BioWorld International the company was attracted to the asset because of its product differentiation potential and because it targets an area with significant unmet need

Hans-Dieter Volk, head of the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and director of the Institute for Medical Immunology in Berlin, told BioWorld International: "Our work opens the door to two developments

It's a number that would be of interest to the CHMP," Santhera CEO Thomas Meier told BioWorld International

investors," Justin Gover, CEO told BioWorld International

Ninety-five percent of them get acquired – that's just a given," Jan De Kerpel, analyst at KBC Securities in Brussels, Belgium, told BioWorld International

Matthew Berriman, a co-author of the paper, and group leader for parasite genomics at the Wellcome Trust Sanger Institute, told BioWorld International: "This work lays everything out for the entire tapeworm research community to mine, and provides a shortcut to drug discovery

Ravi Anand, chief medical officer at Milan, Italy-based Newron told BioWorld International

By the end, we hope to have a lead candidate, know the mode of action and be ready to consider clinical development," Thompson told BioWorld International

Company (Location) Funding Institution Amount (US$M) Type Details Date OCTOBER Addex Therapeutics SA (Geneva) Swiss Commission for Technology and Innovation CHF0.7 ($0.748) Grant For development of allosteric modulators for neurodegenerative and psychiatric diseases 10/3/12 Advanced Cancer Therapeutics Inc. (Louisville, Ky.) National Cancer Institute $0.158 Phase I SBIR grant To support the development of an inhibitor of glycolysis targeting 6-phosphofructo-2 kinase/fructose 2,6-biphosphatase 3